As of today (2024-06-20), Ovoca Bio's share price is €0.01.
Ovoca Bio's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2023 was €-0.02. Hence, Ovoca Bio's Price-to-Free-Cash-Flow Ratio for today is N/A.
The historical rank and industry rank for Ovoca Bio's Price-to-Free-Cash-Flow or its related term are showing as below:
DUB:OVXA's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 32.09 * Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was -23.50% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was -33.50% per year.
During the past 13 years, Ovoca Bio's highest 3-Year average Free Cash Flow per Share Growth Rate was 78.50% per year. The lowest was -329.10% per year. And the median was -5.50% per year.
Ovoca Bio Price-to-Free-Cash-Flow Historical Data
The historical data trend for Ovoca Bio's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Ovoca Bio's Price-to-Free-Cash-Flow
For the Biotechnology subindustry, Ovoca Bio's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ovoca Bio's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ovoca Bio's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Ovoca Bio's Price-to-Free-Cash-Flow falls into.
Ovoca Bio Price-to-Free-Cash-Flow Calculation
Ovoca Bio's Price-to-Free-Cash-Flow ratio for today is calculated as
Ovoca Bio's Share Price of today is €0.01.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ovoca Bio's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2023 was €-0.02.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Ovoca Bio (DUB:OVXA) Price-to-Free-Cash-Flow Explanation
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Ovoca Bio Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of Ovoca Bio's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Ovoca Bio PLC is a life science investment company. The company is engaged in investing in the development and commercialization of novel product candidates for the treatment of female sexual dysfunctions. The group has two business segments, bio-pharmaceutical and investment, which are operated principally in Russian Federation and investment activities operated from Bermuda, and with administrative activities in the Republic of Ireland. Its product candidate includes IVIX - Libicore - a novel synthetic peptide, administrated through a nasal spray.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DUB:OVXA has been successfully added to your 